• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by LENZ Therapeutics Inc.

    2/17/26 4:03:03 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LENZ alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Lenz Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    52635N103

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    52635N103


    1Names of Reporting Persons

    Ridgeback Capital Investments L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    52635N103


    1Names of Reporting Persons

    Ridgeback Capital Investments LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    52635N103


    1Names of Reporting Persons

    Ridgeback Capital Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the shares. Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Lenz Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    201 Lomas Santa Fe Dr., Suite 300, Solana Beach, CA 92075
    Item 2. 
    (a)Name of person filing:

    Ridgeback Capital Investments L.P.
    (b)Address or principal business office or, if none, residence:

    30 Star Island Drive, Miami Beach, FL 33139
    (c)Citizenship:

    DE
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    52635N103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ridgeback Capital Investments L.P.
     
    Signature:/s/ Nicole Venezia
    Name/Title:Nicole Venezia, General Counsel
    Date:02/17/2026
     
    Ridgeback Capital Investments LLC
     
    Signature:/s/ Nicole Venezia
    Name/Title:Nicole Venezia, General Counsel
    Date:02/17/2026
     
    Ridgeback Capital Management LLC
     
    Signature:/s/ Nicole Venezia
    Name/Title:Nicole Venezia, General Counsel
    Date:02/17/2026
    Exhibit Information

    https://www.sec.gov/Archives/edgar/data/1423994/000110465924083538/tm2420256d1_ex99-1.htm

    Get the next $LENZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LENZ

    DatePrice TargetRatingAnalyst
    5/12/2026$12.00Overweight → Neutral
    Piper Sandler
    4/14/2025$38.00 → $51.00Overweight
    Piper Sandler
    3/18/2025$60.00Buy
    TD Cowen
    9/27/2024$37.00Outperform
    Raymond James
    8/12/2024$38.00Buy
    H.C. Wainwright
    4/15/2024Outperform
    William Blair
    4/15/2024$32.00Outperform
    Leerink Partners
    4/10/2024$34.00Buy
    Citigroup
    More analyst ratings

    $LENZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LENZ Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded LENZ Therapeutics from Overweight to Neutral and set a new price target of $12.00

    5/12/26 8:21:06 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler resumed coverage on LENZ Therapeutics with a new price target

    Piper Sandler resumed coverage of LENZ Therapeutics with a rating of Overweight and set a new price target of $51.00 from $38.00 previously

    4/14/25 8:17:08 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on LENZ Therapeutics with a new price target

    TD Cowen initiated coverage of LENZ Therapeutics with a rating of Buy and set a new price target of $60.00

    3/18/25 7:53:26 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    SEC Filings

    View All

    SEC Form 10-Q filed by LENZ Therapeutics Inc.

    10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/11/26 4:10:32 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

    5/11/26 4:07:49 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by LENZ Therapeutics Inc.

    DEFA14A - LENZ Therapeutics, Inc. (0001815776) (Filer)

    4/28/26 4:42:46 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by George Jeffrey P.

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/30/26 8:47:03 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Schimmelpennink Evert B.

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/30/26 8:46:58 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chevallard Daniel R.

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    3/30/26 8:46:52 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mccollum James W bought $239,278 worth of shares (10,500 units at $22.79) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    11/10/25 4:13:53 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Chevallard Daniel R. bought $50,017 worth of shares (2,198 units at $22.76), increasing direct ownership by 69% to 5,386 units (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    11/7/25 7:42:43 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chevallard Daniel R. bought $49,988 worth of shares (3,188 units at $15.68) (SEC Form 4)

    4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

    5/15/24 4:13:06 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENZ Therapeutics to Participate in Upcoming Investor Conferences

    SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: William Blair 46th Annual Growth Stock Conference Date: June 2, 2026Location: Chicago, ILFormat: 1x1 investor meetings 2026 Jefferies Global Healthcare ConferenceDate: June 3, 2026Location: New York, NYFormat: 1x1 investor meetings Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Jun

    5/26/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presby

    5/11/26 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

    SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.

    5/4/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Leadership Updates

    Live Leadership Updates

    View All

    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

    WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

    4/1/25 7:00:00 AM ET
    $ABOS
    $CLYM
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lucy Therapeutics Appoints Kim Drapkin as Board Chair

    Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st

    10/15/24 8:00:00 AM ET
    $ABOS
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

    Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that the Company will host a Key Opinion Leader ("KOL") event on Tuesday, June 18, 2024 at 8:00 a.m. ET. The event will highlight real-world insights by Key Opinion Leaders and Principal Investigators on the current treatment landscape for presbyopia and their perspectiv

    6/10/24 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Financials

    Live finance-specific insights

    View All

    LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded sales force on-track to be fully deployed by the end of Q2 2026 Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presby

    5/11/26 4:05:00 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

    SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.

    5/4/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

    Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ)

    3/24/26 8:00:00 AM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LENZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENZ Therapeutics Inc.

    SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/14/24 4:00:05 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by LENZ Therapeutics Inc.

    SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

    11/8/24 5:08:56 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by LENZ Therapeutics Inc.

    SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

    7/29/24 4:12:50 PM ET
    $LENZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care